Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

Data Compilation
#PharmaFlow

Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals

Stock Recap
#PipelineProspector

DOXY 200

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

44 API Suppliers, 17 USDMF, 10 CEP/COS, 1 JDMF, 2 EU WC, 2 KDMF, 15 NDC API, 1 VMF, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

37 Drugs in Development

37 Drugs in Development

FINISHED DOSAGE FORMULATIONS

224 FDF Dossiers, 184 FDA Orange Book, 2 Europe, 15 Canada, 23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE, CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE, SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG, TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 18 SPI Pharma, 12 DKSH, 7 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 12 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 33 BASF, 1 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 3 Finar, 12 Gangwal Chemicals, 8 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 40 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 22 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

100 Fillers, Diluents & Binders, 65 Coating Systems & Additives, 45 Disintegrants & Superdisintegrants, 42 Thickeners and Stabilizers, 39 Direct Compression, 35 Controlled & Modified Release, 33 Granulation, 30 Solubilizers, 28 Film Formers & Plasticizers, 28 Parenteral, 25 Taste Masking, 21 Lubricants & Glidants, 20 Topical, 19 Chewable & Orodispersible Aids, 18 Co-Processed Excipients, 11 Rheology Modifiers, 9 Empty Capsules, 8 Emulsifying Agents, 7 API Stability Enhancers, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

50 News #PharmaBuzz

50 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Regulatory FDF Prices

MARKET PLACE

66 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents

14 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
04/04/2025	Yancheng Suhai Pharmaceutical Co	China	Samoh Pharmaceutical Co., Ltd.	20110630-101-F-59-02	Doxycycline Hyclate	2011-06-30	Yancheng Suhai Pharmaceutical Co., Ltd	China	No. 92 E.Jiankang Road, Dafeng City, Jiangsu, China
04/04/2025	Yancheng Suhai Pharmaceutical Co	China	Samoh Pharmaceutical Co., Ltd.	20220527-101-F-98-05	Doxycycline Hyclate	2022-05-27	Yancheng Suhai Pharmaceutical Co.,Ltd	China	Huafeng Industrial Park, Dafeng Port Economic Development Zone, Dafeng District, Yancheng City, Jiangsu Province, China

DOXY 200

DOXY 200

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

44 API Suppliers

17 USDMF

10 CEP/COS

1 JDMF

2 EU WC

2 KDMF

15 NDC API

1 VMF

19 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

37 Drugs in Development

FINISHED DOSAGE FORMULATIONS

224 FDF Dossiers

184 FDA Orange Book

2 Europe

15 Canada

23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE

TABLET;ORAL - EQ 75MG BASE

TABLET;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE

CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE

SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

18 SPI Pharma

12 DKSH

7 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

4 ACG Worldwide

12 Actylis

2 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

33 BASF

1 Clariant

11 Corel Pharma Chem

7 DFE Pharma

3 Finar

12 Gangwal Chemicals

8 Ideal Cures Pvt Ltd

5 Ingredion Pharma Solutions

40 Kerry

5 Kima Chemical

6 Lonza Capsugel

22 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

4 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

29 Roquette

14 Seppic

CAPSULE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons